Markets
Vanda Pharmaceuticals Inc. (VNDA)
VNDANASDAQ-GMBiotechnology: Pharmaceutical Preparations
$4.08
-0.0100 (-0.24%) today
At the close, Nov 10, 4:00 PM ET. After hours $4.08 –
-0.24% 1D
- Market cap
- $246.72m
- P/E
- –
- EPS, last 4 quarters
- $-2.69
- Dividend yield
- –
- Day range
- $4.00 to $4.18
- 52-week range
- $3.57 to $9.94
- Average volume
- 1.10m
- Previous close
- $4.09
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $13.25, +224.8% from here
$10.00now $4.08$20.00
Earnings
next estimate $-0.3200Next report
Dec 2025
+78.9%
Mar 2026
-54.7%
Jun 2026
-103.9%
Sep 2026
+48.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $57.22m | $51.72m | $50.53m | $69.81m |
| Gross profit | $53.38m | $48.56m | $46.97m | $65.66m |
| Operating income | -$40.35m | -$50.22m | -$63.81m | -$23.52m |
| Net income | -$141.19m | -$48.57m | -$62.51m | -$22.56m |
Last four quarters: revenue $229.28m, margin -119.9%, free cash flow -$139.96m
News
8 latest- Vanda (VNDA) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- Vanda Pharmaceuticals Inc. Reports Third Quarter 2026 Financial ResultsFintel · Oct 28, 2026
- Vanda Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · Oct 28, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 28, 2026
- VANDA PHARMACEUTICALS Q3 Loss Narrows RTTNews · Oct 28, 2026
- Vanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 Study RTTNews · Oct 27, 2026
- Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Zacks · Oct 22, 2026
- XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Zacks · Oct 15, 2026
The company
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- vandapharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.